董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adam S. Grossman | 男 | Founder,President,Chief Executive Officer and Director | 49 | 1023.73万美元 | 444.20 | 2026-02-25 |
| Jerrold B. Grossman | 男 | Director,Co-Founder and Vice Chairman | 78 | 44.00万美元 | 85.15 | 2026-02-25 |
| Lawrence P. Guiheen | 男 | Director | 75 | 43.50万美元 | 49.02 | 2026-02-25 |
| Alison C. Finger | 女 | Director | 62 | 41.62万美元 | 19.21 | 2026-02-25 |
| Eduardo Rene Salas | 男 | Director | -- | 41.25万美元 | 5.16 | 2026-02-25 |
| Young T. Kwon | 男 | Director | -- | 44.50万美元 | 50.89 | 2026-02-25 |
| Steven A. Elms | 男 | Chairman and Director | 62 | 44.62万美元 | 223.02 | 2026-02-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adam S. Grossman | 男 | Founder,President,Chief Executive Officer and Director | 49 | 1023.73万美元 | 444.20 | 2026-02-25 |
| Kaitlin Kestenberg | 女 | Chief Operating Officer and SVP, Compliance | -- | 348.86万美元 | 38.60 | 2026-02-25 |
| Terry Kohler | 男 | Chief Financial Officer and Treasurer | 48 | 229.69万美元 | 未持股 | 2026-02-25 |
董事简历
中英对照 | 中文 | 英文- Adam S. Grossman
-
Adam S. Grossman从2007年开始一直担任该公司的董事，他从2011年10月开始担任该公司的总裁兼首席执行官，从2007年到2011年10月，担任该公司的总裁兼首席运营官。Grossman先生拥有超过16年的血液与血浆行业的从业经验。创立该公司前，从1994年到2011年，Grossman先生担任National Hospital Specialties and GenesisBPS的执行副总裁，他拥有上市新产品、建立并管理全国和国际销售团队、管理临床试验以及完成诸多业务开发交易的工作经验。在这之前，他在医学免疫公司（MedImmune, Inc.）任职，他在该公司的呼吸道合胞病与巨细胞病毒免疫球蛋白的营销团队任职，并在美国红十字会（American Red Cross）任职，他在那里与生物医学服务部门合作上市了新产品。Grossman先生在美利坚大学（American University）获得国际商务与营销学的工商管理理学学士学位。
Adam S. Grossman,Mr. Grossman has been a director of the Company since 2007 has served as the Company's President and Chief Executive Officer since October 2011 and as the Company's President and Chief Operating Officer between 2007 and October 2011. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. - Adam S. Grossman从2007年开始一直担任该公司的董事，他从2011年10月开始担任该公司的总裁兼首席执行官，从2007年到2011年10月，担任该公司的总裁兼首席运营官。Grossman先生拥有超过16年的血液与血浆行业的从业经验。创立该公司前，从1994年到2011年，Grossman先生担任National Hospital Specialties and GenesisBPS的执行副总裁，他拥有上市新产品、建立并管理全国和国际销售团队、管理临床试验以及完成诸多业务开发交易的工作经验。在这之前，他在医学免疫公司（MedImmune, Inc.）任职，他在该公司的呼吸道合胞病与巨细胞病毒免疫球蛋白的营销团队任职，并在美国红十字会（American Red Cross）任职，他在那里与生物医学服务部门合作上市了新产品。Grossman先生在美利坚大学（American University）获得国际商务与营销学的工商管理理学学士学位。
- Adam S. Grossman,Mr. Grossman has been a director of the Company since 2007 has served as the Company's President and Chief Executive Officer since October 2011 and as the Company's President and Chief Operating Officer between 2007 and October 2011. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University.
- Jerrold B. Grossman
-
Jerrold B. Grossman，他一直担任公司的董事（2007年以来）。他曾担任ADMA的兼职首席执行官（从2007年到2011年10月）。他是National Hospital Specialties公司（专业等离子体衍生品发行企业）的创始人兼首席执行官，也曾担任该公司的首席执行官（1980年以来）。此外，他是GenesisBPS公司（医疗设备公司，专注于血液采集和加工设备）的创始人兼总裁，也曾担任该公司的总裁（1990年以来）。此前，他曾任职the New York Blood Center、Immuno-U.S。公司，此前曾担任Bergen Community Blood Services公司的董事会主席。目前，他是the New Jersey Blood Bank Task Force的成员，以及the New Jersey Association of Blood Bank Professionals的创始人兼董事。他是Pascack Bancorp公司的创始人兼董事，目前担任其审计委员会成员。他也曾为多家政府机构和国际组织提供咨询服务。他持有Fairleigh Dickinson University的经济学和财务学士学位、Fairleigh Dickinson University的工商管理硕士学位、Pace University的商业管理公共事业博士学位。
Jerrold B. Grossman,Dr. Grossman has been a director of the Company since 2007. He served as the Chief Executive Officer of ADMA, on a part-time basis, between 2007 and October 2011. He is the founder and Chief ExecutiveOfficer of Technomed, Inc. formerly National Hospital Specialties, a wholesaler of specialty biological and pharmaceutical products, and has served as Chief Executive Officer of that company since 1980. Additionally, Dr. Grossman is the founder and President of GenesisBPS, a medical device firm specializing in blood collection and processing equipment, and has served as President of that company since 1990. Previously, he has held positions at the New York Blood Center, Immuno-U.S., Inc. and previously served as the Chairman of the Board of Bergen Community Blood Services. Currently, Dr. Grossman is a member of the New Jersey Blood Bank Task Force and a founder and director of the New Jersey Association of Blood Bank Professionals. He was a founder and former director of Pascack Bancorp, Inc. which was acquired by Lakeland Bancorp, Inc. in January 2016 and is currently a member of the Corporate Advisory Council of Lakeland Bancorp Inc. Dr. Grossman has also provided consulting services to various government agencies and international organizations. He received a B.A. in Economics and Finance from Fairleigh Dickinson University, an M.B.A. from Fairleigh Dickinson University, and his D.P.S. in Business Management from Pace University. - Jerrold B. Grossman，他一直担任公司的董事（2007年以来）。他曾担任ADMA的兼职首席执行官（从2007年到2011年10月）。他是National Hospital Specialties公司（专业等离子体衍生品发行企业）的创始人兼首席执行官，也曾担任该公司的首席执行官（1980年以来）。此外，他是GenesisBPS公司（医疗设备公司，专注于血液采集和加工设备）的创始人兼总裁，也曾担任该公司的总裁（1990年以来）。此前，他曾任职the New York Blood Center、Immuno-U.S。公司，此前曾担任Bergen Community Blood Services公司的董事会主席。目前，他是the New Jersey Blood Bank Task Force的成员，以及the New Jersey Association of Blood Bank Professionals的创始人兼董事。他是Pascack Bancorp公司的创始人兼董事，目前担任其审计委员会成员。他也曾为多家政府机构和国际组织提供咨询服务。他持有Fairleigh Dickinson University的经济学和财务学士学位、Fairleigh Dickinson University的工商管理硕士学位、Pace University的商业管理公共事业博士学位。
- Jerrold B. Grossman,Dr. Grossman has been a director of the Company since 2007. He served as the Chief Executive Officer of ADMA, on a part-time basis, between 2007 and October 2011. He is the founder and Chief ExecutiveOfficer of Technomed, Inc. formerly National Hospital Specialties, a wholesaler of specialty biological and pharmaceutical products, and has served as Chief Executive Officer of that company since 1980. Additionally, Dr. Grossman is the founder and President of GenesisBPS, a medical device firm specializing in blood collection and processing equipment, and has served as President of that company since 1990. Previously, he has held positions at the New York Blood Center, Immuno-U.S., Inc. and previously served as the Chairman of the Board of Bergen Community Blood Services. Currently, Dr. Grossman is a member of the New Jersey Blood Bank Task Force and a founder and director of the New Jersey Association of Blood Bank Professionals. He was a founder and former director of Pascack Bancorp, Inc. which was acquired by Lakeland Bancorp, Inc. in January 2016 and is currently a member of the Corporate Advisory Council of Lakeland Bancorp Inc. Dr. Grossman has also provided consulting services to various government agencies and international organizations. He received a B.A. in Economics and Finance from Fairleigh Dickinson University, an M.B.A. from Fairleigh Dickinson University, and his D.P.S. in Business Management from Pace University.
- Lawrence P. Guiheen
-
Lawrence P. Guiheen，他于2012年7月当选公司的董事，拥有25年以上的血液和血浆行业经验。2013年7月以来，他一直担任Kedrion BioPharma公司（位于意大利巴尔加、新泽西李堡）的首席商务官。Kedrion公司在全球市场治疗血友病、新生儿溶血病、免疫和神经系统紊乱。2013年7月之前，他曾担任Guiheen and Associates公司（咨询集团，专注于生物制药、制药和医疗设备商业化）的负责人。2011年7月之前，他曾任职Baxter Healthcare Corporation30年以上。最近，他曾担任全球血友病特许经营总经理（始于2010年12月）、Baxter Healthcare公司的生物科学部门的全球生物制药总裁（2010年3月至2010年12月）、BioPharmaceuticals US公司的总裁（2004年1月至2010年3月）。他一直担任生物科学高级管理团队的成员14年以上，拥有领导全球和国内商业组织的等离子体和重组疗法的丰富经验。他是the Plasma Proteins Therapeutics Association （PPTA）的前全球董事会主席，以及California Healthcare Institute （CHI）的董事会前任成员。他持有Rutgers University的工商管理学士学位。
Lawrence P. Guiheen,Mr. Guiheen has been a director of the Company since July 2012 and is currently the Chairman of the Company’s Governance and Nominations Committee and a member of the Company’s Audit Committee.Since July 2013 Mr. Guiheen has been Chief Commercial Officer of Kedrion BioPharma, Inc., based in Barga, Italy and Fort Lee, New Jersey. Kedrion markets therapies globally for hemophilia, hemolytic disease of the newborn, immune and neurological disorders. Prior to July 2013 Mr. Guiheen was principal of Guiheen and Associates, a consulting group that specialized in biopharmaceutical, pharmaceutical and medical device commercialization. Before July 2011 Mr. Guiheen was with Baxter Healthcare Corporation for over 30 years. Most recently he held the positions of General Manager Global Hemophilia Franchise from December 2010 to July 2011 President of Global BioPharmaceuticals for Baxter Healthcare's BioScience Division from March 2010 to December 2010 and President of BioPharmaceuticals US from January 2004 to March 2010. Mr. Guiheen is past Chairman of the Global Board of Directors for the Plasma Proteins Therapeutics Association PPTA and a past member of the Board of Directors of California Healthcare Institute (CHI). Mr. Guiheen holds a B.A. degree in business administration from Rutgers University. - Lawrence P. Guiheen，他于2012年7月当选公司的董事，拥有25年以上的血液和血浆行业经验。2013年7月以来，他一直担任Kedrion BioPharma公司（位于意大利巴尔加、新泽西李堡）的首席商务官。Kedrion公司在全球市场治疗血友病、新生儿溶血病、免疫和神经系统紊乱。2013年7月之前，他曾担任Guiheen and Associates公司（咨询集团，专注于生物制药、制药和医疗设备商业化）的负责人。2011年7月之前，他曾任职Baxter Healthcare Corporation30年以上。最近，他曾担任全球血友病特许经营总经理（始于2010年12月）、Baxter Healthcare公司的生物科学部门的全球生物制药总裁（2010年3月至2010年12月）、BioPharmaceuticals US公司的总裁（2004年1月至2010年3月）。他一直担任生物科学高级管理团队的成员14年以上，拥有领导全球和国内商业组织的等离子体和重组疗法的丰富经验。他是the Plasma Proteins Therapeutics Association （PPTA）的前全球董事会主席，以及California Healthcare Institute （CHI）的董事会前任成员。他持有Rutgers University的工商管理学士学位。
- Lawrence P. Guiheen,Mr. Guiheen has been a director of the Company since July 2012 and is currently the Chairman of the Company’s Governance and Nominations Committee and a member of the Company’s Audit Committee.Since July 2013 Mr. Guiheen has been Chief Commercial Officer of Kedrion BioPharma, Inc., based in Barga, Italy and Fort Lee, New Jersey. Kedrion markets therapies globally for hemophilia, hemolytic disease of the newborn, immune and neurological disorders. Prior to July 2013 Mr. Guiheen was principal of Guiheen and Associates, a consulting group that specialized in biopharmaceutical, pharmaceutical and medical device commercialization. Before July 2011 Mr. Guiheen was with Baxter Healthcare Corporation for over 30 years. Most recently he held the positions of General Manager Global Hemophilia Franchise from December 2010 to July 2011 President of Global BioPharmaceuticals for Baxter Healthcare's BioScience Division from March 2010 to December 2010 and President of BioPharmaceuticals US from January 2004 to March 2010. Mr. Guiheen is past Chairman of the Global Board of Directors for the Plasma Proteins Therapeutics Association PPTA and a past member of the Board of Directors of California Healthcare Institute (CHI). Mr. Guiheen holds a B.A. degree in business administration from Rutgers University.
- Alison C. Finger
-
AlisonC.Finger，芬格女士自2018年2月起担任我们的首席商务官。此前，她曾担任我们的高级副总裁，营销和产品发布（2015年8月以来）。加入公司之前，她曾担任Bristol Meyers Squibb公司（Bristol Meyers Squibb，Inc.“；BMS”；）的职务，并不断被提拔为全球领导职务，在那里她曾负责推出血液学/肿瘤学、神经退行性疾病、肝炎、艾滋病毒/艾滋病、糖尿病的全球、区域和国家品牌，类风湿性关节炎和偏头痛/疼痛。在BMS，她从2004年7月到2007年6月担任全球商业化病毒学Vice President，从2007年7月到2009年5月担任澳大利亚和新西兰总经理，从2009年5月到2012年12月担任阿尔茨海默氏症/神经科学全球商业化副总裁，从2012年12月到2014年5月担任血液学全球商业化副总裁。Finger女士在圣劳伦斯大学（St.Lawrence University）获得英语写作学士学位，并在杜克大学（Duke University）福夸商学院（Fuqua School of Business）获得工商管理硕士学位。
Alison C. Finger,Ms. Finger has served as our Chief Commercial Officer since February 2018. Prior to this role, she served as our Senior Vice President, Marketing and Product Launch since August 2015. Prior to joining the Company, Ms. Finger served in roles with increasing responsibility at Bristol Meyers Squibb, Inc. “BMS”, beginning her career in consumer medicines before progressing to global leadership roles where she was responsible for launching global, regional and national brands in hematology/oncology, neurodegenerative diseases, hepatitis, HIV/AIDS, diabetes, rheumatoid arthritis and migraine/pain. At BMS, she served as Vice President, Global Commercialization Virology from July 2004 to June 2007 Managing Director, Australia & New Zealand from July 2007 to May 2009 VP Global Commercialization, Alzheimer’s/Neuroscience from May 2009 to December 2012 and VP Global Commercialization, Hematology from December 2012 to May 2014. Ms. Finger received her B.A. in English Writing from St. Lawrence University and her M.B.A. from the Fuqua School of Business at Duke University. - AlisonC.Finger，芬格女士自2018年2月起担任我们的首席商务官。此前，她曾担任我们的高级副总裁，营销和产品发布（2015年8月以来）。加入公司之前，她曾担任Bristol Meyers Squibb公司（Bristol Meyers Squibb，Inc.“；BMS”；）的职务，并不断被提拔为全球领导职务，在那里她曾负责推出血液学/肿瘤学、神经退行性疾病、肝炎、艾滋病毒/艾滋病、糖尿病的全球、区域和国家品牌，类风湿性关节炎和偏头痛/疼痛。在BMS，她从2004年7月到2007年6月担任全球商业化病毒学Vice President，从2007年7月到2009年5月担任澳大利亚和新西兰总经理，从2009年5月到2012年12月担任阿尔茨海默氏症/神经科学全球商业化副总裁，从2012年12月到2014年5月担任血液学全球商业化副总裁。Finger女士在圣劳伦斯大学（St.Lawrence University）获得英语写作学士学位，并在杜克大学（Duke University）福夸商学院（Fuqua School of Business）获得工商管理硕士学位。
- Alison C. Finger,Ms. Finger has served as our Chief Commercial Officer since February 2018. Prior to this role, she served as our Senior Vice President, Marketing and Product Launch since August 2015. Prior to joining the Company, Ms. Finger served in roles with increasing responsibility at Bristol Meyers Squibb, Inc. “BMS”, beginning her career in consumer medicines before progressing to global leadership roles where she was responsible for launching global, regional and national brands in hematology/oncology, neurodegenerative diseases, hepatitis, HIV/AIDS, diabetes, rheumatoid arthritis and migraine/pain. At BMS, she served as Vice President, Global Commercialization Virology from July 2004 to June 2007 Managing Director, Australia & New Zealand from July 2007 to May 2009 VP Global Commercialization, Alzheimer’s/Neuroscience from May 2009 to December 2012 and VP Global Commercialization, Hematology from December 2012 to May 2014. Ms. Finger received her B.A. in English Writing from St. Lawrence University and her M.B.A. from the Fuqua School of Business at Duke University.
- Eduardo Rene Salas
-
Eduardo Rene Salas，自2024年起担任公司董事，并担任公司审计委员会成员。自2022年以来，Salas先生一直担任Intra-cellular Therapies, Inc.的审计委员会成员。从2021年至2023年，Salas先生担任Embody，Inc.的首席独立董事和审计委员会主席。Embody，Inc.是一家被齐默巴奥米特控股公司收购的私营公司，从2020年至2022年，Salas先生担任Wellstat Therapeutics，LLC的首席财务官，该公司是一家专注于药品开发和分销的公司。在任职Wellstat之前，Salas先生曾于2002年担任安永会计师事务所（“安永”）的高级客户服务审计合伙人，直至2019年退休。Salas先生拥有得克萨斯大学圣安东尼奥分校的工商管理学士学位。在安永任职期间，萨拉斯先生在哈佛商学院和西北大学家乐氏管理学院完成了战略领导力课程。
Eduardo Rene Salas,has been a director of the Company since 2024 and serves as a member of the Company's Audit Committee. Since 2022, Mr. Salas has served on the audit committee of Intra-Cellular Therapies, Inc. From 2021 to 2023, Mr. Salas served as the lead independent director and audit committee chair of Embody, Inc., a private company that was acquired by Zimmer Biomet Holdings, Inc. From 2020 to 2022, Mr. Salas served as Chief Financial Officer of Wellstat Therapeutics, LLC, a company focused on the development and distribution of pharmaceutical drugs. Prior to his tenure at Wellstat, Mr. Salas served as a senior client serving audit partner of Ernst & Young LLP ("EY") from 2002 until retirement in 2019. Mr. Salas has a B.A. in business administration from The University of Texas at San Antonio. During his time at EY, Mr. Salas completed Strategic Leadership programs at Harvard Business School and at Northwestern University, Kellogg School of Management. - Eduardo Rene Salas，自2024年起担任公司董事，并担任公司审计委员会成员。自2022年以来，Salas先生一直担任Intra-cellular Therapies, Inc.的审计委员会成员。从2021年至2023年，Salas先生担任Embody，Inc.的首席独立董事和审计委员会主席。Embody，Inc.是一家被齐默巴奥米特控股公司收购的私营公司，从2020年至2022年，Salas先生担任Wellstat Therapeutics，LLC的首席财务官，该公司是一家专注于药品开发和分销的公司。在任职Wellstat之前，Salas先生曾于2002年担任安永会计师事务所（“安永”）的高级客户服务审计合伙人，直至2019年退休。Salas先生拥有得克萨斯大学圣安东尼奥分校的工商管理学士学位。在安永任职期间，萨拉斯先生在哈佛商学院和西北大学家乐氏管理学院完成了战略领导力课程。
- Eduardo Rene Salas,has been a director of the Company since 2024 and serves as a member of the Company's Audit Committee. Since 2022, Mr. Salas has served on the audit committee of Intra-Cellular Therapies, Inc. From 2021 to 2023, Mr. Salas served as the lead independent director and audit committee chair of Embody, Inc., a private company that was acquired by Zimmer Biomet Holdings, Inc. From 2020 to 2022, Mr. Salas served as Chief Financial Officer of Wellstat Therapeutics, LLC, a company focused on the development and distribution of pharmaceutical drugs. Prior to his tenure at Wellstat, Mr. Salas served as a senior client serving audit partner of Ernst & Young LLP ("EY") from 2002 until retirement in 2019. Mr. Salas has a B.A. in business administration from The University of Texas at San Antonio. During his time at EY, Mr. Salas completed Strategic Leadership programs at Harvard Business School and at Northwestern University, Kellogg School of Management.
- Young T. Kwon
-
Young T. Kwon，自2021年起担任ADMA的董事，目前担任薪酬委员会和审计委员会各自的主席。2022年4月至2024年9月，权博士在Alchemab Therapeutics担任首席执行官，该公司是一家生物技术公司，专注于发现和开发神经变性和肿瘤学中的天然保护性抗体。他最近还担任了Lightstone Ventures的顾问，Lightstone Ventures是一家投资于生物技术和医疗设备公司的风险投资公司。权博士于2011年1月至2021年1月期间在摩蒙塔制药担任过多种领导职务，担任高级管理人员。权博士此前担任Momenta的首席财务和业务官，负责业务发展、战略、财务、投资者关系和商业。权博士牵头进行了公共股权融资，筹集了近5亿美元，并牵头以65亿美元的价格将该公司出售给了强生。在加入Momenta之前，权博士是渤健的业务发展专业人士，曾推动过多种交易。权博士此前曾任职于风险投资公司Advanced Technology Ventures，投资于处于早期阶段的生物技术和医疗设备公司。权博士获得麻省理工学院生物学学士学位和哈佛大学生物化学和分子药理学博士学位。
Young T. Kwon,has been a director of ADMA since 2021 and currently serves as the Chairman of each of the Compensation Committee and Audit Committee. From April 2022 to September 2024, Dr. Kwon served as Chief Executive Officer at Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology. He was also recently an Advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies. Dr. Kwon held a variety of leadership roles as a senior executive at Momenta Pharmaceuticals from January 2011 until January 2021. Dr. Kwon was previously Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Dr. Kwon led public equity financings raising nearly $500 million and led the company's sale to Johnson & Johnson for $6.5 billion. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions. Dr. Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies. Dr. Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University. - Young T. Kwon，自2021年起担任ADMA的董事，目前担任薪酬委员会和审计委员会各自的主席。2022年4月至2024年9月，权博士在Alchemab Therapeutics担任首席执行官，该公司是一家生物技术公司，专注于发现和开发神经变性和肿瘤学中的天然保护性抗体。他最近还担任了Lightstone Ventures的顾问，Lightstone Ventures是一家投资于生物技术和医疗设备公司的风险投资公司。权博士于2011年1月至2021年1月期间在摩蒙塔制药担任过多种领导职务，担任高级管理人员。权博士此前担任Momenta的首席财务和业务官，负责业务发展、战略、财务、投资者关系和商业。权博士牵头进行了公共股权融资，筹集了近5亿美元，并牵头以65亿美元的价格将该公司出售给了强生。在加入Momenta之前，权博士是渤健的业务发展专业人士，曾推动过多种交易。权博士此前曾任职于风险投资公司Advanced Technology Ventures，投资于处于早期阶段的生物技术和医疗设备公司。权博士获得麻省理工学院生物学学士学位和哈佛大学生物化学和分子药理学博士学位。
- Young T. Kwon,has been a director of ADMA since 2021 and currently serves as the Chairman of each of the Compensation Committee and Audit Committee. From April 2022 to September 2024, Dr. Kwon served as Chief Executive Officer at Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology. He was also recently an Advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies. Dr. Kwon held a variety of leadership roles as a senior executive at Momenta Pharmaceuticals from January 2011 until January 2021. Dr. Kwon was previously Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Dr. Kwon led public equity financings raising nearly $500 million and led the company's sale to Johnson & Johnson for $6.5 billion. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions. Dr. Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies. Dr. Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.
- Steven A. Elms
-
Steven A. Elms，自2011任职以来，他担任独立董事和审计委员会的主席和财务专家。他也在提名和薪酬委员会任职。他目前是Aisling Capital（一家领先的投资生命科学公司的私募股权基金）的管理合伙人。此前，他是Hambrecht & Quist的生命科学投资银行部门的高级成员。他从事融资和并购交易60多年并帮助客户筹集超过33亿美元的资本。他获得凯洛格管理研究所的工商管理硕士学位，以及斯坦福大学的人体生物学学士学位。
Steven A. Elms has served as the chairman of board of directors since May 2019 and served as Chief Executive Officer from May 2019 until November 2020. Mr. Elms currently serves as a Managing Partner of Aisling Capital LLC/Aisling Capital Management LP, a life sciences investment firm, which he joined in 2000. Prior to joining Aisling, Mr. Elms served as a principal in the life sciences investment banking group of Chase H&Q formerly Hambrecht and Quist Group Inc.. Mr. Elms has served as a director for Zosano Pharma Corp, a clinical stage biopharmaceutical company, since May 2018 Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, since August 2019 and ADMA Biologics, Inc., a commercial biopharmaceutical company, since July 2007. Previously, Mr. Elms served on the board of directors of Loxo Oncology, Inc. from July 2013 to February 2019 Ambit Biosciences Corp. from 2001 to 2014 MAP Pharmaceuticals, Inc. from 2004 to 2011 and has served on the boards of directors of a number of private companies. Mr. Elms received a B.A. in Human Biology from Stanford University and a M.B.A. from the Kellogg School of Management at Northwestern University. - Steven A. Elms，自2011任职以来，他担任独立董事和审计委员会的主席和财务专家。他也在提名和薪酬委员会任职。他目前是Aisling Capital（一家领先的投资生命科学公司的私募股权基金）的管理合伙人。此前，他是Hambrecht & Quist的生命科学投资银行部门的高级成员。他从事融资和并购交易60多年并帮助客户筹集超过33亿美元的资本。他获得凯洛格管理研究所的工商管理硕士学位，以及斯坦福大学的人体生物学学士学位。
- Steven A. Elms has served as the chairman of board of directors since May 2019 and served as Chief Executive Officer from May 2019 until November 2020. Mr. Elms currently serves as a Managing Partner of Aisling Capital LLC/Aisling Capital Management LP, a life sciences investment firm, which he joined in 2000. Prior to joining Aisling, Mr. Elms served as a principal in the life sciences investment banking group of Chase H&Q formerly Hambrecht and Quist Group Inc.. Mr. Elms has served as a director for Zosano Pharma Corp, a clinical stage biopharmaceutical company, since May 2018 Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, since August 2019 and ADMA Biologics, Inc., a commercial biopharmaceutical company, since July 2007. Previously, Mr. Elms served on the board of directors of Loxo Oncology, Inc. from July 2013 to February 2019 Ambit Biosciences Corp. from 2001 to 2014 MAP Pharmaceuticals, Inc. from 2004 to 2011 and has served on the boards of directors of a number of private companies. Mr. Elms received a B.A. in Human Biology from Stanford University and a M.B.A. from the Kellogg School of Management at Northwestern University.
高管简历
中英对照 | 中文 | 英文- Adam S. Grossman
Adam S. Grossman从2007年开始一直担任该公司的董事，他从2011年10月开始担任该公司的总裁兼首席执行官，从2007年到2011年10月，担任该公司的总裁兼首席运营官。Grossman先生拥有超过16年的血液与血浆行业的从业经验。创立该公司前，从1994年到2011年，Grossman先生担任National Hospital Specialties and GenesisBPS的执行副总裁，他拥有上市新产品、建立并管理全国和国际销售团队、管理临床试验以及完成诸多业务开发交易的工作经验。在这之前，他在医学免疫公司（MedImmune, Inc.）任职，他在该公司的呼吸道合胞病与巨细胞病毒免疫球蛋白的营销团队任职，并在美国红十字会（American Red Cross）任职，他在那里与生物医学服务部门合作上市了新产品。Grossman先生在美利坚大学（American University）获得国际商务与营销学的工商管理理学学士学位。
Adam S. Grossman,Mr. Grossman has been a director of the Company since 2007 has served as the Company's President and Chief Executive Officer since October 2011 and as the Company's President and Chief Operating Officer between 2007 and October 2011. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University.- Adam S. Grossman从2007年开始一直担任该公司的董事，他从2011年10月开始担任该公司的总裁兼首席执行官，从2007年到2011年10月，担任该公司的总裁兼首席运营官。Grossman先生拥有超过16年的血液与血浆行业的从业经验。创立该公司前，从1994年到2011年，Grossman先生担任National Hospital Specialties and GenesisBPS的执行副总裁，他拥有上市新产品、建立并管理全国和国际销售团队、管理临床试验以及完成诸多业务开发交易的工作经验。在这之前，他在医学免疫公司（MedImmune, Inc.）任职，他在该公司的呼吸道合胞病与巨细胞病毒免疫球蛋白的营销团队任职，并在美国红十字会（American Red Cross）任职，他在那里与生物医学服务部门合作上市了新产品。Grossman先生在美利坚大学（American University）获得国际商务与营销学的工商管理理学学士学位。
- Adam S. Grossman,Mr. Grossman has been a director of the Company since 2007 has served as the Company's President and Chief Executive Officer since October 2011 and as the Company's President and Chief Operating Officer between 2007 and October 2011. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University.
- Kaitlin Kestenberg
Kaitlin Kestenberg，2012年加入公司担任临床研究经理，获得多个晋升和职责不断增加的职位。Kestenberg女士于2023年4月至2024年3月期间担任公司合规与项目运营高级副总裁，于2021年5月至2023年3月期间担任合规与项目管理副总裁兼分析和流程开发代理主管，于2019年4月至2021年5月期间担任合规与项目管理副总裁，并于2018年1月至2019年3月期间担任合规、项目管理和临床运营高级总监。在加入公司之前，她曾在阿索尔达治疗公司和默沙东公司担任临床运营、质量运营和合规方面日益重要的职责。Kestenberg女士拥有纽约州立大学奥尔巴尼分校的学士学位和Seton Hall大学的M.S.J.学位。
Kaitlin Kestenberg,joined the Company as Clinical Research Manager in 2012 and has received multiple promotions and positions of increasing responsibility. Ms. Kestenberg served as the Company's Senior Vice President, Compliance & Project Operations from April 2023 through March 2024, as Vice President, Compliance & Project Management and Acting Head of Analytical and Process Development from May 2021 through March 2023, as Vice President, Compliance & Project Management from April 2019 until May 2021 and as Senior Director, Compliance, Project Management & Clinical Operations from January 2018 through March 2019. Prior to joining the Company, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics, Inc. and Merck & Co. Inc. Ms. Kestenberg holds a B.A. from the State University of New York at Albany and an M.S.J. from Seton Hall University.- Kaitlin Kestenberg，2012年加入公司担任临床研究经理，获得多个晋升和职责不断增加的职位。Kestenberg女士于2023年4月至2024年3月期间担任公司合规与项目运营高级副总裁，于2021年5月至2023年3月期间担任合规与项目管理副总裁兼分析和流程开发代理主管，于2019年4月至2021年5月期间担任合规与项目管理副总裁，并于2018年1月至2019年3月期间担任合规、项目管理和临床运营高级总监。在加入公司之前，她曾在阿索尔达治疗公司和默沙东公司担任临床运营、质量运营和合规方面日益重要的职责。Kestenberg女士拥有纽约州立大学奥尔巴尼分校的学士学位和Seton Hall大学的M.S.J.学位。
- Kaitlin Kestenberg,joined the Company as Clinical Research Manager in 2012 and has received multiple promotions and positions of increasing responsibility. Ms. Kestenberg served as the Company's Senior Vice President, Compliance & Project Operations from April 2023 through March 2024, as Vice President, Compliance & Project Management and Acting Head of Analytical and Process Development from May 2021 through March 2023, as Vice President, Compliance & Project Management from April 2019 until May 2021 and as Senior Director, Compliance, Project Management & Clinical Operations from January 2018 through March 2019. Prior to joining the Company, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics, Inc. and Merck & Co. Inc. Ms. Kestenberg holds a B.A. from the State University of New York at Albany and an M.S.J. from Seton Hall University.
- Terry Kohler
特里·科勒于2025年12月加入公司，担任执行财务顾问。在加入公司之前，他曾于2024年10月至2025年5月被收购，担任OptiNose，Inc.（“OptiNose”）（纳斯达克：OPTN）的首席财务官，该公司是一家专注于接受耳鼻喉（ENT）和过敏专科治疗的患者的制药公司。从2021年7月到2024年10月，Kohler先生在皮肤病治疗公司Verrica Pharmaceuticals Inc.（“Verrica制药”）担任首席财务官，在那里他支持启动传染性软疣局部治疗的商业准备以及研发管道投资。在加入Verrica制药之前，Kohler先生曾在远藤制药 PLC（“Endo”）担任越来越重要的职务，包括2020年3月至2021年7月的副总裁–企业发展和财务主管。在加入远藤之前，他完成了强生 MBA领导力发展项目，并曾在多家投行工作。Kohler先生拥有迪金森学院的国际Biness和管理学士学位和北卡罗来纳大学的金融与创业工商管理硕士学位。他是一名注册管理会计师。
Terry Kohler joined the Company in December 2025 as its Executive Financial Advisor. Prior to joining the Company, he served as Chief Financial Officer of OptiNose, Inc. ("OptiNose") (Nasdaq: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, from October 2024 through its acquisition in May 2025. From July 2021 until October 2024, Mr. Kohler served as Chief Financial Officer of Verrica Pharmaceuticals Inc. ("Verrica Pharmaceuticals"), a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for mollcum contagiosum and research and development pipeline investments. Prior to joining Verrica Pharmaceuticals, Mr. Kohler held roles of increasing responsibility at Endo International PLC ("Endo"), including Vice President – Corporate Development and Treasurer from March 2020 to July 2021. Before joining Endo, he completed the Johnson & Johnson MBA Leadership Development program and worked at several investment banking firms. Mr. Kohler holds a B.A. in International Biness and Management from Dickinson College and an M.B.A. in Finance & Entrepreneurship from the University of North Carolina. He is a Certified Management Accountant.- 特里·科勒于2025年12月加入公司，担任执行财务顾问。在加入公司之前，他曾于2024年10月至2025年5月被收购，担任OptiNose，Inc.（“OptiNose”）（纳斯达克：OPTN）的首席财务官，该公司是一家专注于接受耳鼻喉（ENT）和过敏专科治疗的患者的制药公司。从2021年7月到2024年10月，Kohler先生在皮肤病治疗公司Verrica Pharmaceuticals Inc.（“Verrica制药”）担任首席财务官，在那里他支持启动传染性软疣局部治疗的商业准备以及研发管道投资。在加入Verrica制药之前，Kohler先生曾在远藤制药 PLC（“Endo”）担任越来越重要的职务，包括2020年3月至2021年7月的副总裁–企业发展和财务主管。在加入远藤之前，他完成了强生 MBA领导力发展项目，并曾在多家投行工作。Kohler先生拥有迪金森学院的国际Biness和管理学士学位和北卡罗来纳大学的金融与创业工商管理硕士学位。他是一名注册管理会计师。
- Terry Kohler joined the Company in December 2025 as its Executive Financial Advisor. Prior to joining the Company, he served as Chief Financial Officer of OptiNose, Inc. ("OptiNose") (Nasdaq: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, from October 2024 through its acquisition in May 2025. From July 2021 until October 2024, Mr. Kohler served as Chief Financial Officer of Verrica Pharmaceuticals Inc. ("Verrica Pharmaceuticals"), a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for mollcum contagiosum and research and development pipeline investments. Prior to joining Verrica Pharmaceuticals, Mr. Kohler held roles of increasing responsibility at Endo International PLC ("Endo"), including Vice President – Corporate Development and Treasurer from March 2020 to July 2021. Before joining Endo, he completed the Johnson & Johnson MBA Leadership Development program and worked at several investment banking firms. Mr. Kohler holds a B.A. in International Biness and Management from Dickinson College and an M.B.A. in Finance & Entrepreneurship from the University of North Carolina. He is a Certified Management Accountant.